{"name":"Mountain Diabetes and Endocrine Center","slug":"mountain-diabetes-and-endocrine-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Faster Insulin Aspart (Fiasp®)","genericName":"Faster Insulin Aspart (Fiasp®)","slug":"faster-insulin-aspart-fiasp","indication":"Type 1 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Faster Insulin Aspart (Fiasp®)","genericName":"Faster Insulin Aspart (Fiasp®)","slug":"faster-insulin-aspart-fiasp","phase":"marketed","mechanism":"Faster insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOcWJ5QmhUVGJHV0tTY3pWd3VWLVhQSndKLTZXd25pZThySHlXS1V5NzM2M1ZfUllsY3dWS29KUHNiSXgxd2Npa3R2RjA5QW1KbVlmWWhoaUpFVFU0TE85bmhzdDhTd2g1ZVVmTUV1eWRkYldXd1BmbTF4djc3MW14V0E5ZzNKZUppYlJqSURaTkZPdjNBMmNyZg?oc=5","date":"2023-11-13","type":"pipeline","source":"UCHealth","summary":"What is Zepbound? Does this new weight loss drug work better than Wegovy and Ozempic? Will it cut costs? - UCHealth","headline":"What is Zepbound? Does this new weight loss drug work better than Wegovy and Ozempic? Will it cut costs?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNODF2YXJ4VHpGX1FkVnE3YTRhOXdMbzZ3QW5YVlh6MklMQ21mRGR3TjJxNEtyclBJZXhBSGYwM1B6ZldHeVAtZzFZMDJMS3pnN2NnVUhhU2V5ZkRWb1R3Nk1mNUl4Y2tlMGFaajkyaEVHUWhpbHlVMDQxUUZSRHh6RlhUNHp1TE1KX3VwdFZ3eGNtaHV1SlRWUnVsQWRQdVJ5SWNLZ1NMV2J6VWM?oc=5","date":"2016-06-11","type":"pipeline","source":"Fierce Pharma","summary":"Novo Nordisk beefs up safety case for Tresiba in market-share fight with Sanofi - Fierce Pharma","headline":"Novo Nordisk beefs up safety case for Tresiba in market-share fight with Sanofi","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}